BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 27795442)

  • 1. Replication-Deficient Particles: New Insights into the Next Generation of Bluetongue Virus Vaccines.
    Celma CC; Stewart M; Wernike K; Eschbaumer M; Gonzalez-Molleda L; Breard E; Schulz C; Hoffmann B; Haegeman A; De Clercq K; Zientara S; van Rijn PA; Beer M; Roy P
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of bluetongue Disabled Infectious Single Animal (DISA) vaccine for different serotypes by VP2 exchange or incorporation of chimeric VP2.
    Feenstra F; Pap JS; van Rijn PA
    Vaccine; 2015 Feb; 33(6):812-8. PubMed ID: 25510389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VP2-serotyped live-attenuated bluetongue virus without NS3/NS3a expression provides serotype-specific protection and enables DIVA.
    Feenstra F; Maris-Veldhuis M; Daus FJ; Tacken MG; Moormann RJ; van Gennip RG; van Rijn PA
    Vaccine; 2014 Dec; 32(52):7108-14. PubMed ID: 25454873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective efficacy of Bluetongue virus-like and subvirus-like particles in sheep: presence of the serotype-specific VP2, independent of its geographic lineage, is essential for protection.
    Stewart M; Dovas CI; Chatzinasiou E; Athmaram TN; Papanastassopoulou M; Papadopoulos O; Roy P
    Vaccine; 2012 Mar; 30(12):2131-9. PubMed ID: 22285887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bluetongue virus without NS3/NS3a expression is not virulent and protects against virulent bluetongue virus challenge.
    Feenstra F; van Gennip RGP; Maris-Veldhuis M; Verheij E; van Rijn PA
    J Gen Virol; 2014 Sep; 95(Pt 9):2019-2029. PubMed ID: 24914064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bluetongue viruses based on modified-live vaccine serotype 6 with exchanged outer shell proteins confer full protection in sheep against virulent BTV8.
    van Gennip RG; van de Water SG; Maris-Veldhuis M; van Rijn PA
    PLoS One; 2012; 7(9):e44619. PubMed ID: 23049753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strong protection induced by an experimental DIVA subunit vaccine against bluetongue virus serotype 8 in cattle.
    Anderson J; Hägglund S; Bréard E; Riou M; Zohari S; Comtet L; Olofson AS; Gélineau R; Martin G; Elvander M; Blomqvist G; Zientara S; Valarcher JF
    Vaccine; 2014 Nov; 32(49):6614-21. PubMed ID: 25312275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep.
    Celma CC; Boyce M; van Rijn PA; Eschbaumer M; Wernike K; Hoffmann B; Beer M; Haegeman A; De Clercq K; Roy P
    J Virol; 2013 Sep; 87(17):9856-64. PubMed ID: 23824810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the immune response afforded by a subunit vaccine candidate against bluetongue virus in mice and sheep.
    Mohamed DKA; Du J; Gao S; Tian Z; Zhang G; Huang D; Du R; Kang B; Liu G; Luo J; Yin H
    Vet Microbiol; 2018 Jun; 219():40-48. PubMed ID: 29778203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-propiolactone inactivated bivalent bluetongue virus vaccine containing Montanide ISA-71VG adjuvant induces long-term immune response in sheep against serotypes 4 and 16 even after 3 years of controlled vaccine storage.
    Zhugunissov K; Bulatov Y; Taranov D; Yershebulov Z; Koshemetov Z; Zhunushov A; Renukaradhya GJ; Tabynov K; Abduraimov Y
    Vet Microbiol; 2018 Nov; 226():23-30. PubMed ID: 30389040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection.
    Kochinger S; Renevey N; Hofmann MA; Zimmer G
    Vet Res; 2014 Jun; 45(1):64. PubMed ID: 24928313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of cross-protection of bluetongue virus serotype 4 with other serotypes in sheep.
    Zulu GB; Venter EH
    J S Afr Vet Assoc; 2014 Oct; 85(1):1041. PubMed ID: 25686101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of replication-defective virus-based vaccines that confer full protection in sheep against virulent bluetongue virus challenge.
    Matsuo E; Celma CC; Boyce M; Viarouge C; Sailleau C; Dubois E; Bréard E; Thiéry R; Zientara S; Roy P
    J Virol; 2011 Oct; 85(19):10213-21. PubMed ID: 21795358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plant-produced Bluetongue chimaeric VLP vaccine candidates elicit serotype-specific immunity in sheep.
    Mokoena NB; Moetlhoa B; Rutkowska DA; Mamputha S; Dibakwane VS; Tsekoa TL; O'Kennedy MM
    Vaccine; 2019 Sep; 37(41):6068-6075. PubMed ID: 31471154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection.
    Roy P; Bishop DH; LeBlois H; Erasmus BJ
    Vaccine; 1994 Jul; 12(9):805-11. PubMed ID: 7975859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines against bluetongue in Europe.
    Savini G; MacLachlan NJ; Sanchez-Vizcaino JM; Zientara S
    Comp Immunol Microbiol Infect Dis; 2008 Mar; 31(2-3):101-20. PubMed ID: 17765305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-/-) mice.
    Marín-López A; Otero-Romero I; de la Poza F; Menaya-Vargas R; Calvo-Pinilla E; Benavente J; Martínez-Costas JM; Ortego J
    Antiviral Res; 2014 Oct; 110():42-51. PubMed ID: 25057758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microspheres-prime/rMVA-boost vaccination enhances humoral and cellular immune response in IFNAR(-/-) mice conferring protection against serotypes 1 and 4 of bluetongue virus.
    Marín-López A; Calvo-Pinilla E; Barriales D; Lorenzo G; Benavente J; Brun A; Martínez-Costas JM; Ortego J
    Antiviral Res; 2017 Jun; 142():55-62. PubMed ID: 28322923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nature and duration of protective immunity to bluetongue virus infection.
    Roy P
    Dev Biol (Basel); 2003; 114():169-83. PubMed ID: 14677687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA vaccine prime and recombinant FPV vaccine boost: an important candidate immunization strategy to control bluetongue virus type 1.
    Li J; Yang T; Xu Q; Sun E; Feng Y; Lv S; Zhang Q; Wang H; Wu D
    Appl Microbiol Biotechnol; 2015 Oct; 99(20):8643-52. PubMed ID: 26048472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.